Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

422 related articles for article (PubMed ID: 21562035)

  • 1. WEE1 kinase targeting combined with DNA-damaging cancer therapy catalyzes mitotic catastrophe.
    De Witt Hamer PC; Mir SE; Noske D; Van Noorden CJ; Würdinger T
    Clin Cancer Res; 2011 Jul; 17(13):4200-7. PubMed ID: 21562035
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting Wee1-like protein kinase to treat cancer.
    Stathis A; Oza A
    Drug News Perspect; 2010 Sep; 23(7):425-9. PubMed ID: 20862394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting WEE1 Kinase in Cancer.
    Matheson CJ; Backos DS; Reigan P
    Trends Pharmacol Sci; 2016 Oct; 37(10):872-881. PubMed ID: 27427153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WEE1 inhibition sensitizes osteosarcoma to radiotherapy.
    PosthumaDeBoer J; Würdinger T; Graat HC; van Beusechem VW; Helder MN; van Royen BJ; Kaspers GJ
    BMC Cancer; 2011 Apr; 11():156. PubMed ID: 21529352
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Forced activation of Cdk1 via wee1 inhibition impairs homologous recombination.
    Krajewska M; Heijink AM; Bisselink YJ; Seinstra RI; Silljé HH; de Vries EG; van Vugt MA
    Oncogene; 2013 Jun; 32(24):3001-8. PubMed ID: 22797065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. WEE1 kinase limits CDK activities to safeguard DNA replication and mitotic entry.
    Elbæk CR; Petrosius V; Sørensen CS
    Mutat Res; 2020; 819-820():111694. PubMed ID: 32120135
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiosensitization of p53 mutant cells by PD0166285, a novel G(2) checkpoint abrogator.
    Wang Y; Li J; Booher RN; Kraker A; Lawrence T; Leopold WR; Sun Y
    Cancer Res; 2001 Nov; 61(22):8211-7. PubMed ID: 11719452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. WEE1 inhibition and genomic instability in cancer.
    Vriend LE; De Witt Hamer PC; Van Noorden CJ; Würdinger T
    Biochim Biophys Acta; 2013 Dec; 1836(2):227-35. PubMed ID: 23727417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wee1 Kinase: A Potential Target to Overcome Tumor Resistance to Therapy.
    Esposito F; Giuffrida R; Raciti G; Puglisi C; Forte S
    Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639030
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Small-molecule inhibition of Wee1 kinase by MK-1775 selectively sensitizes p53-deficient tumor cells to DNA-damaging agents.
    Hirai H; Iwasawa Y; Okada M; Arai T; Nishibata T; Kobayashi M; Kimura T; Kaneko N; Ohtani J; Yamanaka K; Itadani H; Takahashi-Suzuki I; Fukasawa K; Oki H; Nambu T; Jiang J; Sakai T; Arakawa H; Sakamoto T; Sagara T; Yoshizumi T; Mizuarai S; Kotani H
    Mol Cancer Ther; 2009 Nov; 8(11):2992-3000. PubMed ID: 19887545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wee1 kinase as a target for cancer therapy.
    Do K; Doroshow JH; Kummar S
    Cell Cycle; 2013 Oct; 12(19):3159-64. PubMed ID: 24013427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role for Wee1 in inhibition of G2-to-M transition through the cooperation of distinct human papillomavirus type 1 E4 proteins.
    Knight GL; Turnell AS; Roberts S
    J Virol; 2006 Aug; 80(15):7416-26. PubMed ID: 16840322
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined inhibition of Chk1 and Wee1: in vitro synergistic effect translates to tumor growth inhibition in vivo.
    Carrassa L; Chilà R; Lupi M; Ricci F; Celenza C; Mazzoletti M; Broggini M; Damia G
    Cell Cycle; 2012 Jul; 11(13):2507-17. PubMed ID: 22713237
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In silico analysis of kinase expression identifies WEE1 as a gatekeeper against mitotic catastrophe in glioblastoma.
    Mir SE; De Witt Hamer PC; Krawczyk PM; Balaj L; Claes A; Niers JM; Van Tilborg AA; Zwinderman AH; Geerts D; Kaspers GJ; Peter Vandertop W; Cloos J; Tannous BA; Wesseling P; Aten JA; Noske DP; Van Noorden CJ; Würdinger T
    Cancer Cell; 2010 Sep; 18(3):244-57. PubMed ID: 20832752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphorylation and inactivation of the mitotic inhibitor Wee1 by the nim1/cdr1 kinase.
    Parker LL; Walter SA; Young PG; Piwnica-Worms H
    Nature; 1993 Jun; 363(6431):736-8. PubMed ID: 8515817
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Forced mitotic entry of S-phase cells as a therapeutic strategy induced by inhibition of WEE1.
    Aarts M; Sharpe R; Garcia-Murillas I; Gevensleben H; Hurd MS; Shumway SD; Toniatti C; Ashworth A; Turner NC
    Cancer Discov; 2012 Jun; 2(6):524-39. PubMed ID: 22628408
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological inactivation of CHK1 and WEE1 induces mitotic catastrophe in nasopharyngeal carcinoma cells.
    Mak JP; Man WY; Chow JP; Ma HT; Poon RY
    Oncotarget; 2015 Aug; 6(25):21074-84. PubMed ID: 26025928
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Inhibition of ATR and WEE1 as a Novel Therapeutic Strategy in Triple-Negative Breast Cancer.
    Jin J; Fang H; Yang F; Ji W; Guan N; Sun Z; Shi Y; Zhou G; Guan X
    Neoplasia; 2018 May; 20(5):478-488. PubMed ID: 29605721
    [TBL] [Abstract][Full Text] [Related]  

  • 19. DNA damage detection and repair pathways--recent advances with inhibitors of checkpoint kinases in cancer therapy.
    Ashwell S; Zabludoff S
    Clin Cancer Res; 2008 Jul; 14(13):4032-7. PubMed ID: 18593978
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of the WEE1 inhibitor MK-1775 as single-agent anticancer therapy.
    Guertin AD; Li J; Liu Y; Hurd MS; Schuller AG; Long B; Hirsch HA; Feldman I; Benita Y; Toniatti C; Zawel L; Fawell SE; Gilliland DG; Shumway SD
    Mol Cancer Ther; 2013 Aug; 12(8):1442-52. PubMed ID: 23699655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.